Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.
Garraway, most recently Eli Lilly’s senior vice president, oncology research and development and Lilly research laboratories novel target research, will take up the post as of Oct. 1 and be based in South San Francisco.
Horning, who joined Roche and its Genentech division nearly a decade ago and has been chief medical officer since 2014, will retire as of the end of 2019, Roche said in a statement.
She led the product development organization, oversaw late-stage clinical development, and co-chaired the committee that invests in pivotal registrational trials.
Garraway joined Lilly in 2017 as senior vice president, global development and medical affairs for the oncology division. Before that he was director of the Joint Center for Cancer Precision Medicine, which spanned Harvard teaching hospitals.
In 2010, Garraway, a Harvard graduate, co-founded Foundation Medicine, which provides tumor molecular information.
By John Miller
Source: Reuters
Since it launched in 2018, Accent Therapeutics has busied itself discovering new targets for cancer drugs in the space of RNA-modifying proteins. But the time for lying low is over—just […]
Last week, Novartis was touting positive data showing its repurposed leukemia drug ofatumumab outpaced Sanofi’s Aubagio in a multiple sclerosis trial. Now, Novartis has revealed that the FDA, which was […]
Johnson and Johnson’s experimental two-stage vaccine for protection against Ebola virus disease is among eight medicines backed by the European Medicines Agency’s human medicines committee (CHMP) at its May meeting. […]
